The Growing Appeal of Wegovy in Modern Weight Care

In recent years, the conversation around weight loss has shifted dramatically. No longer is it simply about willpower or crash diets; instead, science-backed medical interventions have taken center stage. Among these, has emerged as a household name, sparking both hope and curiosity. Approved by the U.S. Food and Drug Administration (FDA) for chronic weight management, Wegovy (semaglutide) is a once-weekly injectable medication that mimics a hormone called GLP-1, which regulates appetite and food intake. Its rise in popularity is not accidental. With global obesity rates climbing—according to the World Health Organization, obesity has nearly tripled since 1975—the demand for effective, medically supervised solutions has never been higher.

What makes Wegovy particularly noteworthy is its strict eligibility criteria, which are anchored to body mass index (BMI). But as interest grows, so does confusion. Many people wonder: Am I a candidate? Does my BMI alone determine my access? And what happens if I use it without meeting the guidelines? This article will walk you through the relationship between Wegovy and BMI, explaining who qualifies and why these distinctions matter for your health, safety, and long-term success. Whether you are considering for yourself or supporting a loved one, understanding the science behind the numbers is the first step toward an informed decision.

Understanding BMI: The Basics and Its Calculation

Body mass index (BMI) is a simple numeric measure derived from a person’s weight and height. It was developed in the 19th century by Belgian statistician Adolphe Quetelet and has since become a global screening tool for weight categories. The formula is straightforward: BMI = weight (kg) ÷ height (m²). For those using pounds and inches, it is weight (lb) ÷ height (in²) × 703. For example, a person weighing 70 kg and standing 1.75 m tall has a BMI of 22.9, which falls in the normal range. The World Health Organization classifies BMI into several categories:

• Underweight: BMI less than 18.5
• Normal weight: BMI 18.5–24.9
• Overweight: BMI 25.0–29.9
• Obesity class I: BMI 30.0–34.9
• Obesity class II: BMI 35.0–39.9
• Obesity class III (severe): BMI 40 or higher

While BMI is easy to calculate and widely used, it is not a direct measure of body fat or health. It does not distinguish between muscle and fat, nor does it account for fat distribution. For instance, a muscular athlete may have a high BMI but low body fat. Conversely, an older adult with low muscle mass may have a normal BMI yet carry excess visceral fat. In Hong Kong, where the population is predominantly Chinese, research has shown that health risks associated with obesity begin at a lower BMI than in Caucasian populations. A 2021 study from the University of Hong Kong found that the optimal BMI cut-off for identifying metabolic syndrome in Hong Kong Chinese adults was 23.5, lower than the international threshold of 25. This nuance is crucial when discussing , as eligibility criteria may need to be adapted for different ethnic groups.

FDA-Approved BMI Criteria for Wegovy Use

The FDA approved Wegovy in June 2021 for chronic weight management in adults who meet specific BMI thresholds. These criteria are based on large-scale clinical trials, including the STEP program, which demonstrated significant weight loss compared to placebo. According to the FDA label, Wegovy is indicated for adults with:

• BMI ≥ 30 kg/m² (obesity), or
• BMI ≥ 27 kg/m² (overweight) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea.

For adolescents aged 12 years and older, the criteria are slightly different: BMI at or above the 95th percentile for age and sex, based on CDC growth charts. In Hong Kong, the Department of Health has not issued separate approval for Wegovy, but doctors may prescribe it off-label following international guidelines. It is important to note that these BMI cut-offs are not arbitrary. They were chosen because the risk-benefit ratio of pharmacotherapy is most favorable in these groups, and the clinical trials primarily enrolled participants within these ranges. A 2022 study published in the New England Journal of Medicine showed that participants with a BMI of 30 or higher lost an average of 14.9% of their body weight over 68 weeks on Wegovy, compared to 2.4% with placebo. For those with a BMI of 27–29.9 and a comorbidity, the weight loss was similarly impressive.

However, these criteria are a starting point, not a final verdict. They do not account for individual variations in metabolism, lifestyle, or cultural factors. For example, a Hong Kong resident with a BMI of 27.5 and prediabetes might qualify, but so might someone with a BMI of 32 and no comorbidities. The key is that BMI is a screening tool, not a diagnostic one. As we will explore, relying solely on BMI can miss important health signals.

Why BMI Alone May Not Tell the Full Health Story

BMI has long been criticized for its oversimplification of health. It does not measure body fat percentage, waist circumference, or visceral fat—all of which are stronger predictors of metabolic disease. A person with a BMI of 26 may have a normal waist size and excellent cardiovascular fitness, while another with the same BMI may have a large waist and insulin resistance. The American Medical Association (AMA) recently acknowledged that BMI is an imperfect measure and recommended that it be used alongside other factors such as waist circumference, blood pressure, and lipid profiles. In Hong Kong, where central obesity is common even at lower BMIs, this is particularly relevant. A 2020 study in the Hong Kong Medical Journal found that 30% of adults with a BMI under 25 had at least one metabolic risk factor, such as high fasting glucose or low HDL cholesterol.

Furthermore, BMI does not capture weight history or the presence of eating disorders. Someone with a BMI of 31 who has struggled with binge eating disorder may not be an appropriate candidate for Wegovy without psychological support. Similarly, a person with a BMI of 28 and a history of pancreatitis or thyroid cancer should not use Wegovy, regardless of BMI. The medication also carries risks of gastrointestinal side effects, gallbladder disease, and, in rare cases, pancreatitis. Therefore, wegovy weight management should never be initiated based on a number alone. A holistic assessment by a healthcare provider is essential. This includes evaluating metabolic markers, lifestyle factors, and the patient’s readiness to commit to long-term therapy.

Who Should Consider Wegovy Beyond BMI: Comorbidities and Metabolic Health

While BMI is the primary gatekeeper for Wegovy eligibility, it is not the only consideration. The FDA explicitly mentions that for individuals with a BMI of 27–29.9, at least one weight-related comorbidity must be present. These comorbidities include, but are not limited to:

• Type 2 diabetes mellitus
• Hypertension (high blood pressure)
• Dyslipidemia (high cholesterol or triglycerides)
• Obstructive sleep apnea
• Non-alcoholic fatty liver disease (NAFLD)
• Polycystic ovary syndrome (PCOS)

In Hong Kong, the prevalence of these conditions is significant. According to the Centre for Health Protection, about 50% of adults aged 15–84 are overweight or obese, and 10% have diabetes. Many of these individuals have a BMI between 27 and 29.9, making them potential candidates for Wegovy. However, a doctor would also consider how well-controlled these conditions are. For example, a person with well-managed hypertension on a single medication might benefit from Wegovy to reduce medication burden, while someone with uncontrolled diabetes might need additional interventions.

Beyond comorbidities, metabolic health markers such as fasting glucose, HbA1c, and liver enzymes can reveal insulin resistance or fatty liver disease even in people with a BMI of 25–26. Some experts argue that these markers should be used to expand eligibility for Wegovy weight management in high-risk populations. For instance, a 2023 consensus statement from the Asian Federation for the Study of Obesity suggested that pharmacotherapy could be considered for Asians with a BMI ≥ 25 and metabolic syndrome, even without a formal comorbidity diagnosis. This reflects the growing understanding that BMI thresholds may need to be lower for Asian populations. A Hong Kong resident with a BMI of 26 and prediabetes might be a more appropriate candidate than someone with a BMI of 30 and no metabolic issues, depending on the clinical picture.

Risks of Using Wegovy Without Meeting BMI Guidelines

Using Wegovy when you do not meet the BMI criteria is not only potentially unsafe but also ethically questionable. First, the medication is not without side effects. Common adverse events include nausea, vomiting, diarrhea, constipation, and abdominal pain. More serious risks include pancreatitis, gallbladder disease, and kidney injury. These risks are generally outweighed by the benefits in individuals with obesity or overweight with comorbidities, but for someone with a BMI of 24, the risk-benefit ratio shifts. Clinical trials did not include such participants, so the safety profile is unknown. Second, using Wegovy without meeting criteria may lead to unnecessary weight loss, which can be harmful. A person with a BMI of 23 who loses 15% of their body weight could become underweight, leading to nutritional deficiencies, bone loss, and immune dysfunction.

Third, there is the issue of supply and access. Wegovy has faced global shortages, and prioritizing it for those who meet the criteria ensures that the most vulnerable patients can access it. In Hong Kong, where the drug is not widely subsidized, off-label use could drive up costs and divert supply from those with severe obesity. Finally, using Wegovy without medical supervision can be dangerous. The medication requires dose titration to minimize side effects, and regular monitoring of kidney function, blood sugar, and mental health is recommended. A 2023 report from the Hong Kong Hospital Authority noted an increase in emergency department visits related to GLP-1 agonists, often due to improper use or lack of follow-up. Therefore, it is crucial to respect the BMI guidelines and work with a healthcare provider.

How Doctors Assess BMI Alongside Other Factors

When a patient asks about Wegovy weight management , a thorough medical evaluation is the first step. Doctors do not simply look at a BMI number and write a prescription. Instead, they conduct a comprehensive assessment that includes:

• Medical history: Weight history, previous weight loss attempts, eating patterns, and mental health screening for depression, anxiety, or eating disorders.
• Physical examination: Waist circumference, blood pressure, and signs of insulin resistance (e.g., acanthosis nigricans).
• Laboratory tests: Fasting glucose, HbA1c, lipid profile, liver function tests, and kidney function tests.
• Lifestyle evaluation: Diet quality, physical activity, sleep, and stress levels.
• Contraindications: Personal or family history of medullary thyroid cancer, multiple endocrine neoplasia syndrome type 2, pancreatitis, or severe gastroparesis.

In Hong Kong, doctors may also consider the patient’s cultural background and dietary habits. For example, a diet high in refined carbohydrates and low in fiber is common, and this can affect metabolic health independently of BMI. A 2022 study from the Chinese University of Hong Kong found that a structured lifestyle program combined with pharmacotherapy led to better outcomes than medication alone. This underscores the importance of a multidisciplinary approach. Doctors may also use tools like the Edmonton Obesity Staging System (EOSS), which stages obesity based on comorbidities and functional status, rather than BMI alone. A patient with a BMI of 28 but severe sleep apnea and joint pain might be staged as EOSS 2 or 3, indicating a higher need for intervention. Thus, the decision to prescribe Wegovy is never black and white; it is a nuanced clinical judgment that balances risks, benefits, and patient preferences.

Key Takeaways for Discussing Wegovy with a Healthcare Provider

If you are considering Wegovy for weight management, the most important step is to have an open, honest conversation with your doctor. Here are the key points to keep in mind:

• Know your BMI and waist circumference. Calculate your BMI, but also measure your waist. For Asians, a waist circumference ≥ 90 cm for men and ≥ 80 cm for women indicates central obesity, even if BMI is normal.
• Be aware of your comorbidities. If you have high blood pressure, diabetes, or sleep apnea, mention them. These can make you eligible for Wegovy even at a lower BMI.
• Understand the commitment. Wegovy is a long-term medication. It works best when combined with a reduced-calorie diet and increased physical activity. It is not a quick fix.
• Ask about risks and side effects. Discuss your personal risk factors, including any history of pancreatitis or thyroid cancer.
• Explore alternatives. If you do not meet the criteria, ask about other options, such as lifestyle programs, other medications, or bariatric surgery.
• Seek credible sources. In Hong Kong, you can consult the Department of Health, the Hong Kong Association for the Study of Obesity, or your family doctor for evidence-based information.

Ultimately, Wegovy weight management is a powerful tool, but it is not for everyone. The BMI criteria exist to protect patients and ensure that those who need it most can access it safely. By understanding these guidelines and working closely with a healthcare provider, you can make an informed decision that prioritizes your long-term health and well-being. Remember, the goal is not just a lower number on the scale, but a healthier, more vibrant life.